Mounjaro®
Starting from £179.99/mo
Start journey Learn moreFor most people, the side effects of Wegovy are at their most noticeable in the first one to four weeks of treatment and typically settle as the body adjusts — though they can return briefly after each dose increase. Clinical trial data and NHS guidance on semaglutide consistently show that gastrointestinal symptoms such as nausea, diarrhoea and indigestion are common, particularly in the early weeks, but are usually mild to moderate and short-lived rather than persistent. These are prescription-only medicines; a GPhC-registered prescriber assesses suitability before any treatment begins, and discussing side effects is a normal part of that conversation. If you are currently experiencing symptoms and wondering whether they are typical, you are almost certainly not alone in asking.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The clearest picture of how Wegovy side effects behave over time comes from the STEP 1 trial, a 68-week study of semaglutide 2.4mg involving nearly 2,000 adults, published in the New England Journal of Medicine. Nausea was the most frequently reported side effect, affecting around 44% of participants in the semaglutide group versus 16% on placebo. Crucially, nausea and vomiting were most common during the dose-escalation period (the months when the weekly dose was stepping up every four weeks) and the rate dropped noticeably once participants reached and held the 2.4mg maintenance dose. That pattern is not a coincidence. Semaglutide slows gastric emptying and signals fullness through the gut; the first weeks of a new dose are when that effect is strongest relative to what the body expects. After several weeks at the same strength, most people find the gut adjusts and symptoms ease. The practical implication is that the side effect experience with Wegovy is not fixed for the duration of treatment, it tends to follow the dosing curve, front-loaded at each step.
For nausea specifically, most people who experience it find it settles within one to two weeks of starting a new dose, provided they are eating smaller portions, avoiding rich or fatty foods, and not lying down immediately after meals, practical steps that the NHS semaglutide guidance recommends. Diarrhoea or constipation can take slightly longer to stabilise, sometimes up to three to four weeks. Fatigue and headache, when they occur, are generally early-adjustment symptoms that resolve within the first fortnight. Injection-site reactions (redness, itching or mild bruising) normally clear within a few days. The full overview of Wegovy side effects covers what each symptom involves and how common it is. For people who find that certain effects do not settle on a given dose, a prescriber can consider extending the time at that dose before moving up, which is one reason clinical review before every dose change matters.
A small proportion of people find that side effects from Wegovy persist beyond the typical window or are severe enough to affect daily life. The question of how long side effects last does not have a single answer, because individual variation is real, gut motility, baseline metabolic rate and prior health conditions all play a role. If nausea is still significant at four weeks on the same dose, a prescriber should know. If you are not experiencing any side effects, that is also a normal and valid experience; some people on Wegovy notice very little, and absence of symptoms does not mean the medicine is not working. What matters clinically is whether weight loss is progressing appropriately and whether the treatment remains safe to continue. One thing our prescribers at nume hear fairly regularly: patients who pushed through tolerable short-term nausea in the first two weeks went on to find it resolved, but patients who had severe, unremitting pain were right to contact us rather than wait.
Most Wegovy side effects are self-limiting, but some require prompt assessment. On 29 January 2026, the MHRA issued a Drug Safety Update specifically highlighting acute pancreatitis as a known, infrequent but potentially serious side effect of GLP-1 medicines, severe stomach pain that spreads to the back, with or without vomiting, should not be dismissed as ordinary nausea and warrants urgent medical attention. Gallbladder problems, including gallstones, are also associated with significant weight loss and can present as sharp pain in the upper right abdomen. Severe dehydration from persistent vomiting or diarrhoea (dry mouth, dizziness, little or no urine) needs medical review rather than home management. Signs of a serious allergic reaction (swelling of the face, throat or tongue, difficulty breathing) require emergency services immediately. The most clinically significant Wegovy side effects are outlined in more detail for anyone who wants to understand where the thresholds sit. Suspected side effects can and should be reported through the MHRA Yellow Card scheme, it helps regulators track emerging patterns in real-world use. If you are unsure whether what you are experiencing is serious, you can also find broader information about Wegovy, including how the medicine works and what to expect from treatment, before contacting a prescriber or calling 111. Our support team is available seven days a week for patients who have questions between scheduled reviews.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.